| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (replaced TA255) |
|
Medicine details |
|
| Medicine name | cabazitaxel (Jevtana®) |
| Formulation | 60 mg concentrate and solvent for solution for infusion |
| Reference number | 775 |
| Indication | In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/10/2011 |
| NICE guidance | |